Better Buy: bluebird bio vs. Gilead Sciences
Gilead Sciences (NASDAQ: GILD) has been leading the hunt to find a treatment for COVID-19. As a result, shares of the company have performed well of late and are up by 18.7% since the year began. Meanwhile, bluebird bio (NASDAQ: BLUE), a biotech company that develops treatments for rare diseases, hasn't had the best of luck recently, with its shares down by 21.9% year to date.
Even with this poor performance, I think there are good reasons to consider buying shares of Bluebird, but is it a better stock pick than Gilead Sciences at the moment? Let's look at both companies' operations and decide which is the better biotech stock to buy today.
Image Source: YCharts
Source Fool.com
